SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following its announcement of a record date for a digital token initiative, drawing significant community discussion around its venture into crypto. This attention is amplified by escalating geopolitical rhetoric, including commentary on Greenland and new tariff threats, which is heavily influencing market sentiment and broader economic concerns. The stock continues to be a focal point for politically charged narratives, with both enthusiastic supporters and market participants expressing strong, polarized views.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending due to its recent announcement to acquire a luxury wine authentication and trading business, diversifying its offerings beyond caviar. However, a public offering at $7.00 per unit has led to significant price volatility and a sharp decline, sparking strong community debate about whether the move signals a legitimate long-term strategy or a "pump and dump" scenario. Investors are actively discussing the immediate impact of the offering and the company's valuation amidst these developments.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its oral drug, soquelitinib, in treating moderate to severe atopic dermatitis, particularly in patients resistant to other therapies. The outstanding efficacy and safety profile from this early data are generating significant community excitement, with many anticipating blockbuster potential and a paradigm shift for inflammation and immunology, while some caution about the trial's small size and potential for a future stock offering.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant, a move widely seen as powerful validation for the platform technology beyond its initial COVID application. The community is actively debating whether this partnership signals NVAX's evolution into a royalty-generating company and if high short interest will trigger a substantial upward move, despite some expressing frustration over the immediate market reaction amidst a broader downturn.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant traction following key innovation awards and its confirmed partnership with Celestial AI, recently acquired by Marvell, igniting optimism for upcoming major customer announcements. The community is actively discussing strong market momentum and a potential gamma squeeze, highlighting the company's unique optical interposer technology as a critical enabler for AI and data center infrastructure.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a major talking point as geopolitical tensions escalate over the US's pursuit of Greenland and potential tariffs, prompting a Danish pension fund to divest from US Treasuries citing credit risk concerns. The community remains sharply divided, with some fearing broader international divestment and higher yields while others anticipate eventual rate cuts amid a slowing economy and increased Fed intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Leerink Partnrs

Leerink Partnrs raised shares of Neumora Therapeutics to a "strong-buy" rating in a research note on Monday...

Leerink Partners Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA)

Leerink Partners initiated coverage on shares of Neumora Therapeutics in a research note on Monday. They issued an "outperform" rating and a $8.00 price objective for the company...

Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer's agitation, eyes higher doses

Neumora Therapeutics (NASDAQ:NMRA) reported top-line results from a Phase IB signal-seeking study of NMRA-511 in agitation associated with dementia due to Alzheimer's disease, with management...

Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $3.00 at Stifel Nicolaus

Stifel Nicolaus lifted their price objective on Neumora Therapeutics from $2.00 to $3.00 and gave the company a "hold" rating in a research note on Monday...

Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold...

Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average...

HC Wainwright Has Optimistic Outlook of NMRA FY2025 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Neumora Therapeutics in a report released on Sunday...

Neumora Therapeutics (NASDAQ:NMRA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01...

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Equity

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

NMRA
Neumora Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NMRA News

NMRANeumora Therapeutics Inc.